Egypt Neurology Clinical Trials Market Report 2022 to 2030

Egypt Neurology Clinical Trials Market Analysis

$ 3999

The Egypt Neurology Clinical Trials market is projected to grow from $14.6 Mn in 2022 to $25.2 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the increasing involvement from both global and local companies, a supportive regulatory environment and a growing pool of qualified professionals. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer, Novartis, Minapharm Pharmaceuticals & EIPICO.

ID: IN10EGCT005 CATEGORY: Clinical Trials GEOGRAPHY: Egypt AUTHOR: Vidhi Upadhyay

Buy Now

Egypt Neurology Clinical Trials Market Executive Summary

The Egypt Neurology Clinical Trials market is projected to grow from $14.6 Mn in 2022 to $25.2 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. Egypt has a robust manufacturing sector and is the MENA region's top manufacturer of pharmaceuticals. According to Pharmaconex, about 9 out of 10 pharmaceuticals taken in the nation are manufactured domestically. Epilepsy is one of the most prevalent neurological illnesses, with a global frequency ranging from 5 to 10 per 1000 people, with significant variations depending on location. In Egypt, the frequency was 6.98 per 1000 people. According to the latest WHO statistics released in 2020, Alzheimer's & Dementia Deaths in Egypt totalled 6,975 or 1.30% of total fatalities.

Egypt has been more involved in neurology clinical trials in recent years. Due to various considerations, including the country's enormous population, the availability of skilled clinical research personnel, and a supportive regulatory framework, there is a rising interest among both global and local pharmaceutical firms in conducting clinical trials in Egypt.

In Egypt, neurology clinical trials are being conducted for a variety of illnesses and ailments, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, and stroke. Alzheimer's disease has received special attention in recent years, with multiple clinical studies ongoing to investigate potential therapies for this devastating disorder.

The Egyptian government has also made measures to encourage the expansion of clinical trials in the nation. The Egyptian Ministry of Health has developed clinical trial standards and a simplified clearance procedure for new studies. In addition, the government has formed the Clinical Trials Ethics Commission, which is in charge of ensuring that clinical trials in the country are done ethically and in accordance with international norms.

In addition to multinational pharmaceutical businesses, some Egyptian companies are involved in neurology clinical trials. These firms are working to provide novel medicines for a variety of neurological illnesses, including epilepsy and Parkinson's disease.

Egypt Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

Since Egypt has a huge population, there is a vast pool of possible patients for clinical studies. Egypt has an advanced healthcare system and a rising number of skilled healthcare workers, including doctors and clinical research specialists. This facilitates pharmaceutical firms conducting clinical trials in the nation. The Egyptian government has developed clinical trial standards and a simplified approval procedure for new studies. In addition, the government has formed the Clinical Trials Ethics Commission, which is in charge of ensuring that clinical trials in the country are done ethically and in accordance with international norms. Clinical trials provide Egyptian patients access to novel therapies that are not yet accessible in the nation. This is especially significant for people suffering from neurological illnesses, for whom therapeutic choices are often restricted.

Market Restraints

Egypt has seen political unrest in recent years, which may generate uncertainty for pharmaceutical firms interested in conducting clinical trials there. Funding for clinical trials in Egypt may be restricted, which may make it difficult for certain pharmaceutical firms to perform studies in the nation. While Egypt has a well-developed healthcare system, there could be insufficient infrastructure in certain locations, making clinical trials in specific areas challenging. Moreover, cultural variations between Egypt and other nations may impact the conduct of clinical studies. To meet these variances, pharmaceutical firms might have to adapt their trial techniques.

Competitive Landscape

Key Players

Pfizer
Novartis
Amgen
Hikma Pharmaceuticals
Minapharm Pharmaceuticals (EGY)
Rameda Pharmaceuticals (EGY)
EIPICO (EGY)
Pharco Pharmaceuticals (EGY)
Delta Pharma (EGY)

Notable Deals

April 2022, Hikma Pharmaceuticals PLC, a worldwide pharmaceutical firm, announced the completion of its purchase of Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'), subject to US Federal Trade Commission clearance.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.